Friday, December 16, 2016

BRIEF-Alnylam Pharmaceuticals announces positive preliminary results from phase 1 study of ALN-TTRsc02

* Alnylam Pharmaceuticals- assuming positive phase 3 data,

co plans to submit NDA,marketing authorisation application

year-end 2017

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)